TY 2013 Form 990

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)
(1) JAMES A BECK........................................................................ BOD MEMBER	2.00 .......................	X
(2) WILLIAM G BEHNKE........................................................................ BOD MEMBER	2.00 .......................	X
(3) JORGE L BENITEZ........................................................................ BOD MEMBER	2.00 .......................	X
(4) PETER B BROCK........................................................................ BOD MEMBER	2.00 .......................	X
(5) A DANA CALLOW JR........................................................................ BOD MEMBER	2.00 .......................	X
(6) SCOTT A CARROLL........................................................................ BOD MEMBER	2.00 .......................	X
(7) ELIZABETH J CLARK........................................................................ BOD MEMBER	2.00 .......................	X
(8) RODMAN N MYERS........................................................................ LIFE MEMBER	2.00 .......................	X
(9) JAMES H DAVIS PHD........................................................................ VICE CHAIR	2.00 .......................3.00	X	X
(10) TIMOTHY DURST........................................................................ CHAIR	2.00 .......................3.00	X	X
(11) BERNARD H GARIL........................................................................ BOD MEMBER	2.00 .......................	X
(12) PAMELA JO HAYLOCK........................................................................ BOD MEMBER	2.00 .......................	X
(13) RAANAN HOROWITZ........................................................................ BOD MEMBER	2.00 .......................	X
(14) RICHARD M JEANNERET........................................................................ BOD MEMBER	2.00 .......................	X
(15) RALPH LAWSON........................................................................ BOD MEMBER	2.00 .......................	X
(16) JOSEPH B KELLEY........................................................................ BOD MEMBER	2.00 .......................	X
(17) MARIE V MCDEMMOND........................................................................ BOD MEMBER	2.00 .......................	X

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)
(18) STEVEN T ROSENMDFACP........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(19) KENNETH M SCHWARTZ........................................................................ SECRETARY/TR	2.00 .......................3.00	X	X		0	0
(20) KATHRYN C VECELLIO........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(21) LOUISE E WARNER........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(22) JAMES E BRADNER........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(23) BETH E HAWLEY........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(24) GILLES LEGAULT........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(25) DONALD PROCTOR........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(26) FRANK O SMITH BOD MEMBER	2.00 .......................	X			0	0
(27) KEITH S WHITE........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(28) GRACIELA C ELETA........................................................................ BOD MEMBER	2.00 .......................	X			0	0
(29) JOHN E WALTER........................................................................ PRES&CEO TER	45.00 .......................3.00		X		628,359	63,346
(30) LOUIS J DEGENNARO........................................................................ PRESIDENT &	45.00 .......................3.00		X		446,200	94,307
(31) JAMES T NANGLE........................................................................ SVP&CFO TERM	45.00 .......................		X		408,402	42,373
(32) ROSEMARIE A LOFFREDO........................................................................ CAO&CFO STAR	45.00 .......................		X		136,466	5,319
(33) LISA STOCKMON........................................................................ EVP-CHIEF MK	45.00 .......................			X	348,455	35,824
(34) GEORGE J OMIROS........................................................................ EVP-CHIEF CA	45.00 .......................			X	334,718	45,253
(35) MARK VELLECA........................................................................ CHIEF POLICY	45.00 .......................			X	323,322	47,780
(36) MARK ROITHMAYR........................................................................ CHIEF DEVELO	45.00 .......................			X	320,714	25,806
(37) BRIAN ROSEN........................................................................ CHIEF POLICY	45.00 .......................			X	282,497	33,649

(A) Name and business address	(B) Description of services	(C) Compensation
OLIVER STAFFING INC, 350 LEXINGTON AV SUITE 401NEW YORKNY10016	TEMP STAFFING	6,567,519
PATIENT ADVOCACY FOUNDATION, 421 BUTLER FARM RDHAMPTONVA23666	PAT ASSIST PROC	4,567,715
MAIL AMERICA, 174 ELKTON FARM RDFORESTVA24551	FUNDRAISING SER	3,745,936
INFOCISION, 325 SPRINGSIDE DRIVEAKRONOH44333	FUNDRASING SERV	1,728,035
PARADYZ MATERA, 5 HANOVER SQUARENEW YORKNY10004	FUNDRAISING SER	1,320,036
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 54

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the United States. See Part IV, line 21	69,785,159	69,785,159
2	Grants and other assistance to individuals in the United States. See Part IV, line 22	51,924,134	51,924,134
3	Grants and other assistance to governments, organizations, and individuals outside the United States. See Part IV, lines 15 and 16	8,540,182	8,540,182
4	Benefits paid to or for members
5	Compensation of current officers, directors, trustees, and key employees ....	818,776	569,152	110,390	139,234
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ....
7	Other salaries and wages	72,881,314	50,661,660	9,826,189	12,393,465
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	4,359,951	2,837,221	714,376	808,354
9	Other employee benefits .......	11,051,482	7,191,706	1,810,781	2,048,995
10	Payroll taxes ...........	5,074,199	3,302,015	831,405	940,779
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	704,547	386,222	118,487	199,838
c	Accounting ...........	276,417	151,527	46,486	78,404
d	Lobbying ...........	558,530	306,176	93,931	158,423
e	Professional fundraising services. See Part IV, line 17	7,178,370			7,178,370
f	Investment management fees ......	198,971	109,074	33,462	56,435
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O) ........	17,118,168	9,383,918	2,878,834	4,855,416
12	Advertising and promotion ....	11,443,327	4,600,579	1,727,542	5,115,206
13	Office expenses .......	24,283,597	10,735,405	3,515,242	10,032,950
14	Information technology ......	5,796,747	3,177,688	974,862	1,644,197
15	Royalties ..
16	Occupancy ...........	8,442,768	5,677,843	1,330,818	1,434,107
17	Travel ............	5,174,411	3,495,450	683,781	995,180
18	Payments of travel or entertainment expenses for any federal, state, or local public officials ......
19	Conferences, conventions, and meetings ....	3,874,939	2,938,562	251,127	685,250
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization .....	3,928,364	2,372,972	750,378	805,014
23	Insurance ..............	600,054	386,432	103,072	110,550
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	MISCELLANEOUS	2,887,044	1,948,337	436,748	501,959
b	DUES & SUBSCRIPTIONS	296,831	119,335	44,811	132,685
c
d
e	All other expenses
25	Total functional expenses. Add lines 1 through 24e	317,198,282	240,600,749	26,282,722	50,314,811
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).	20,809,131	8,971,856		11,837,275

Part X Balance Sheet Check if Schedule O contains a response or note to any line in this Part X ..............
	1	Cash–non-interest-bearing .............	5,620,937	1	6,268,949
2	Savings and temporary cash investments .........	19,656,020	2	20,220,498
3	Pledges and grants receivable, net ...........	7,252,079	3	8,575,572
4	Accounts receivable, net .............	81,719	4	311
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
			5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
			6
7	Notes and loans receivable, net .............		7
8	Inventories for sale or use ..............		8
9	Prepaid expenses and deferred charges ..........	4,851,345	9	4,955,078
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	31,199,936
b	Less: accumulated depreciation .....	10b	14,790,328	10,594,159	10c	16,409,608
11	Investments—publicly traded securities ..........	112,406,398	11	125,935,503
12	Investments—other securities. See Part IV, line 11 .....	75,862,899	12	60,216,008
13	Investments—program-related. See Part IV, line 11 .....		13
14	Intangible assets ...............		14
15	Other assets. See Part IV, line 11 ...........		15
16	Total assets. Add lines 1 through 15 (must equal line 34)......	236,325,556	16	242,581,527
	17	Accounts payable and accrued expenses .........	20,652,928	17	20,275,231
18	Grants payable .................	80,460,957	18	99,130,986
19	Deferred revenue ................	34,202,238	19	26,038,202
20	Tax-exempt bond liabilities .............		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D..		21
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........		22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ....		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................		25
26	Total liabilities. Add lines 17 through 25.........	135,316,123	26	145,444,419
		Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............	90,324,737	27	67,582,758
28	Temporarily restricted net assets ...........	7,775,266	28	26,592,408
29	Permanently restricted net assets ...........	2,909,430	29	2,961,942
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........		30
31	Paid-in or capital surplus, or land, building or equipment fund .....		31
32	Retained earnings, endowment, accumulated income, or other funds		32
33	Total net assets or fund balances ...........	101,009,433	33	97,137,108
34	Total liabilities and net assets/fund balances ........	236,325,556	34	242,581,527

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.
right arrow

Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E.)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in

section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross

receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of

its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses

acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box that describes the type of supporting organization and complete lines 11e through 11h.

Type I

Type II

Type III - Functionally integrated

Type III - Non-functionally integrated

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2).

If the organization received a written determination from the IRS that it is a Type I, Type II, or Type III supporting organization, check this box ..................................................

Since August 17, 2006, has the organization accepted any gift or contribution from any of the
following persons?

(i) A person who directly or indirectly controls, either alone or together with persons described in (ii)

Yes

and (iii) below, the governing body of the supported organization? ................

11g(i)

(ii) A family member of a person described in (i) above? ......................

11g(ii)

(iii) A 35% controlled entity of a person described in (i) or (ii) above? ................

11g(iii)

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization in col. (i) listed in your governing document?		(v) Did you notify the organization in col. (i) of your support?		(vi) Is the organization in col. (i) organized in the U.S.?		(vii) Amount of monetary support
(i) Name of supported organization	(ii) EIN	Yes	No	Yes	No	Yes	No	(vii) Amount of monetary support


Total

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990EZ.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2013

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") ....	238,080,823	270,043,865	282,672,072	279,789,664	302,437,152	1,373,023,576
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	238,080,823	270,043,865	282,672,072	279,789,664	302,437,152	1,373,023,576
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..						194,613,347
6	Public support. Subtract line 5 from line 4.						1,178,410,229

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
7	Amounts from line 4..	238,080,823	270,043,865	282,672,072	279,789,664	302,437,152	1,373,023,576
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	4,962,639	3,145,637	2,705,046	2,260,636	1,203,865	14,277,823
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)..	1,925,834	1,779,485	1,502,044	1,974,227	104,879	7,286,469
11	Total support (Add lines 7 through 10).						1,394,587,868

Gross receipts from related activities, etc. (see instructions) ..................

171,720,181

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and stop here................................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2013 (line 6, column (f) divided by line 11, column (f)) .........

84.500 %

Public support percentage for 2012 Schedule A, Part II, line 14 ...............

87.530 %

16a

33 1/3% support test—2013. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2012. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2013. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2012. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2013

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......
3	Gross receipts from activities that are not an unrelated trade or business under section 513..
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge..
6	Total. Add lines 1 through 5.
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons...
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2013 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2012 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2013 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2012 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests—2013. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ........ right arrow

33 1/3% support tests—2012. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ..... right arrow

Schedule A (Form 990 or 990-EZ) 2013

Page 4

Part IV

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; and Part III, line 12. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Explanation

Schedule A (Form 990 or 990-EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Information about Schedule B (Form 990, 990-EZ, or 990-PF) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, $5,000 or more (in money or
property) from any one contributor. Complete Parts I and II.

Special Rules

For a section 501(c)(3) organization filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi) and received from any one contributor, during the year, a contribution of the
greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 for use exclusively for religious, charitable,
scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and
III.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did
not total more than $1,000. If this box is checked, enter here the total contributions that were received during
the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the General Rule
applies to this organization because it received nonexclusively religious, charitable, etc., contributions of $5,000 or more
during the year ......................... Arrow Bullet

Caution. An organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its
Form 990-EZ or on its Form 990PF, Part I, line 2, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2013)

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Page 2

Name of organization THE LEUKEMIA & LYMPHOMA SOCIETYINC INC

Part I	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	RESTRICTED RESTRICTED RESTRICTED RESTRICTED, RESTRICTEDRESTRICTED	$RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Page 3

Name of organization THE LEUKEMIA & LYMPHOMA SOCIETYINC INC

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Page 4

Name of organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part III

Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
that total more than $1,000 for the year. Complete columns (a) through (e) and the following line entry.
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet

$
Use duplicate copies of Part III if additional space is needed.

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE C
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527
SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

See separate instructions. SchCMd Bullet

Information about Schedule C (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

If the organization answered "Yes" to Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" to Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" to Form 990, Part IV, Line 5 (Proxy Tax) or Form 990-EZ, Part V, line 35c (Proxy Tax), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV.

Political expenditures .................................... SchCMd Bullet

Volunteer hours ........................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ......... SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ...... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ..............

Yes No

Was a correction made? .........................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ................................... SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b.. SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ..........................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Paperwork Reduction Act Notice, see the instructions for Form 990 or 990-EZ.

Cat. No. 50084S

Schedule C (Form 990 or 990-EZ) 2013

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......
b	Total lobbying expenditures to influence a legislative body (direct lobbying) .......
c	Total lobbying expenditures (add lines 1a and 1b) ...................
d	Other exempt purpose expenditures ........................
e	Total exempt purpose expenditures (add lines 1c and 1d) ...............
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ......................................	Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the instructions for lines 2a through 2f on page 4.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2010	(b) 2011	(c) 2012	(d) 2013	(e) Total

2a	Lobbying nontaxable amount

b	Lobbying ceiling amount (150% of line 2a, column(e))

c	Total lobbying expenditures

d	Grassroots nontaxable amount

e	Grassroots ceiling amount (150% of line 2d, column (e))

f	Grassroots lobbying expenditures

Schedule C (Form 990 or 990-EZ) 2013

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response to lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? .........................................

Yes

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ....

Yes

Media advertisements? ....................................

Mailings to members, legislators, or the public? .........................

Publications, or published or broadcast statements? .......................

Yes

239,637

Grants to other organizations for lobbying purposes? .......................

Direct contact with legislators, their staffs, government officials, or a legislative body? ........

Yes

786,711

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ......

Yes

90,017

Other activities? ..........................

Yes

558,530

Total. Add lines 1c through 1i ...............................

1,674,895

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 .................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 .....

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? .......

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ................

Did the organization agree to carry over lobbying and political expenditures from the prior year? ..........

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members .....................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political
expenses for which the section 527(f) tax was paid).

Current year .........................................

Carryover from last year ....................................

Total ............................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ................................

Taxable amount of lobbying and political expenditures (see instructions) ..............

Part IV

Supplemental Information

Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, line 2; and Part ll-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation
SCHEDULE C, PART II-B, LINE 1	LLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, NATIONAL COALITION FOR CANCER RESEARCH, PATIENT ADVOCATE FOUNDATION, AMERICA ASSOCIATION FOR CANCER RESEARCH, CHILDREN'S CAUSE FOR CANCER ADVOCACY, THE CANCER LEADERSHIP COUNCIL AND THE ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.

Return Reference

Explanation

SCHEDULE C, PART II-B, LINE 1

LLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, NATIONAL COALITION FOR CANCER RESEARCH, PATIENT ADVOCATE FOUNDATION, AMERICA ASSOCIATION FOR CANCER RESEARCH, CHILDREN'S CAUSE FOR CANCER ADVOCACY, THE CANCER LEADERSHIP COUNCIL AND THE ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.

Schedule C (Form 990 or 990EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b
SchDMd Bullet

Attach to Form 990. SchDMd Bullet

See separate instructions. SchDMd Bullet

Information about Schedule D (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate contributions to (during year) ...
3	Aggregate grants from (during year) .....
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements .......................	2a
b	Total acreage restricted by conservation easements ..................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 8/17/06, and not on a historic structure listed in the National Register ....................	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .......................................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenues included in Form 990, Part VIII, line 1 ........................ SchDMd Bullet

(ii)

Assets included in Form 990, Part X .............................. SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

Revenues included in Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2013

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No

If "Yes," explain the arrangement in Part XIII and complete the following table:


c	Beginning balance .................................	1c
d	Additions during the year ..............................	1d
e	Distributions during the year .............................	1e
f	Ending balance ...................................	1f

Did the organization include an amount on Form 990, Part X, line 21? .....................

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ........

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a)Current year	(b)Prior year	b (c)Two years back	(d)Three years back	(e)Four years back
1a	Beginning of year balance ....	6,027,657	6,000,186	6,059,994	5,023,902	4,481,610
b	Contributions ........				111,064
c	Net investment earnings, gains, and losses	313,872	482,520	48,916	938,068	563,236
d	Grants or scholarships .....	-215,000	-450,000
e	Other expenditures for facilities and programs ........
f	Administrative expenses ....	-3,831	-5,049	-9,992	-13,040	-20,944
g	End of year balance ......	6,122,698	6,027,657	6,000,186	6,059,994	5,023,902

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

Permanent endowment SchDMd Bullet

48.000 %

Temporarily restricted endowment SchDMd Bullet

52.000 %

The percentages in lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) unrelated organizations ........................

3a(i)

(ii) related organizations ........................

3a(ii)

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a	Land .................
b	Buildings ................
c	Leasehold improvements ............	953,362	434,856	518,506
d	Equipment ................	27,556,719	11,922,469	15,634,250
e	Other .................	2,689,855	2,433,003	256,852
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).).......				16,409,608

Schedule D (Form 990) 2013

Page 3

Part VII

InvestmentsOther Securities. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b)Book value	(c) Method of valuation: Cost or end-of-year market value
(1)Financial derivatives
(2)Closely-held equity interests
(3)Other (A) FUND OF HEDGE FUNDS- OPERATING	54,020,325	F
(B) LIMITED PARTNERSHIP EQUITIES-OPERATI	2,597,869	F
(C) FUND OF HEDGE FUNDS-ENDOWMENT	1,653,526	F
(D) 457B PLAN	1,648,380	F
(E) LIMITED PARTNERSHIP EQUITIES-ENDOWME	295,908	F




Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)	60,216,008

Part VIII

InvestmentsProgram Related. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment		(b) Book value	(c) Method of valuation: Cost or end-of-year market value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability		(b) Book value
Federal income taxes









Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)
2. Liability for uncertain tax positions In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII ..................................................

Schedule D (Form 990) 2013

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return Complete if the organization answered 'Yes' to Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......			1	339,832,605
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains on investments ..........	2a	6,349,371
b	Donated services and use of facilities .........	2b	10,982,172
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d	12,662,047
e	Add lines 2a through 2d .....................			2e	29,993,590
3	Subtract line 2e from line 1.....................			3	309,839,015
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	198,971
b	Other (Describe in Part XIII.) ...........	4b	58,001
c	Add lines 4a and 4b.......................			4c	256,972
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	310,095,987

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' to Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........			1	343,191,816
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities ..........	2a	10,982,172
b	Prior year adjustments ..............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d	15,210,333
e	Add lines 2a through 2d......................			2e	26,192,505
3	Subtract line 2e from line 1.....................			3	316,999,311
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	198,971
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.......................			4c	198,971
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	317,198,282

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
SCHEDULE D, PAGE 2, PART III, LINE 4	THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4	LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART X	LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2014 AND 2013.
SCHEDULE D, PAGE 4, PART XI, LINE 2D	LLS CANADA REVENUE 12,662,047
SCHEDULE D, PAGE 4, PART XI, LINE 4B	LSRP CONTRIBUTION 58,002 ROUNDING -1
SCHEDULE D, PAGE 4, PART XII, LINE 2D	LLS CANADA EXPENSES 11,853,901 FOREIGN CURRENCY TRANSALATION ADJUSTMENT 153,433 ROUNDING -4 WRITE-OFF OF CONTRIBUTIONS RECEIVABLE 3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR -304,286
SCHEDULE D, PAGE 4, PART XIII	LLS MAINTAINS A SMALL PHOTOGRAPH COLLECTION FOR PUBLIC EXHIBITION WHICH HAS AN ESTIMATED VALUE OF BETWEEN 20,000 AND 50,000. AS THIS REPRESENTS A RELATIVELY SMALL PERCENTAGE OF LLS'S ASSETS, IT IS NOT SEPARATELY DISCLOSED IN THE FINANCIAL STATEMENTS OR FOOTNOTES.

Schedule D (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990,Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

See separate instructions. Right pointing arrow large image

Information about Schedule F (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 14b.

For grantmakers.Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? ...............................

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in region	(d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for and investments in region
	EAST ASIA		4	RESEARCH FUNDING	RESEARCH GRANTS	1,548,714
	EUROPE		13	RESEARCH FUNDING	RESEARCH GRANTS	4,389,865
	NORTH AMERICA	7	13	RESEARCH FUNDING	RESEARCH GRANTS	2,601,603
	CENTRAL AMERICA & CARIBBEAN			INVESTMENTS	INVESTMENTS	25,156,350













3a	Sub-total .....	7	30			33,696,532
b	Total from continuation sheets to Part I ...
c	Totals (add lines 3a and 3b)	7	30			33,696,532

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2013

Schedule F (Form 990) 2013

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(i) Method of valuation (book, FMV, appraisal, other)
EAST ASIA & PACIFIC	RESEARCH GRANT	55,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	1,250,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	200,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	THERAPY ACCELERATION	43,713	CHECK	FMV
EUROPE	RESEARCH GRANT	110,000	WIRE	ACCRUAL
EUROPE	RESEARCH GRANT	110,000	WIRE	ACCRUAL
EUROPE	RESEARCH GRANT	1,250,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	398,748	CHECK	ACCRUAL
EUROPE	THERAPY ACCELERATION	750,000	CHECK	FMV
EUROPE	THERAPY ACCELERATION	750,000	CHECK	FMV
EUROPE	THERAPY ACCELERATION	9,554	CHECK	FMV
EUROPE	THERAPY ACCELERATION	1,000,000	CHECK	FMV
EUROPE	THERAPY ACCELERATION	11,563	CHECK	FMV
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	505,999	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	300,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	363,353	CHECK	ACCRUAL
NORTH AMERICA	THERAPY ACCELERATION	25,338	CHECK	FMV
NORTH AMERICA	THERAPY ACCELERATION	5,132	CHECK	FMV

Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .... MediumBullet

Enter total number of other organizations or entities ....................... MediumBullet

Schedule F (Form 990) 2013

Schedule F (Form 990) 2013Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of non-cash assistance	(g) Description of non-cash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2013

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2013

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information (see instructions).

ReturnReference	Explanation
SCHEDULE F, PAGE 1, PART I, LINE 2	FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.
SCHEDULE F, PAGE 1, PART I, LINE 3	EAST ASIA 1,548,714 0 EUROPE 4,389,865 0 NORTH AMERICA 2,601,603 0 CENTRAL AMERICA & CARIBBEAN 0 25,156,350

Schedule F (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. right arrow

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.
right arrow

Information about Schedule G (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.

Form 990-EZ filers are not required to complete this part.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

Yes

If "Yes," list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)		(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
			Yes	No
	MAIL AMERICA COMMUNICATIONS INC 174 ELKTON FARM ROAD FOREST, VA24551	DIRECT MAI		No	3,745,937	-3,745,937
	INFOCISION 325 SPRINSIDE DRIVE AKRON, OH44333	TELEMARKET		No	1,728,035	-1,728,035
	PARADYZ MATERA 5 HANOVER SQUARE 6TH FLOOR NEW YORK, NY10004	DIRECT MAI		No	1,320,036	-1,320,036
	EPSILON DALLAS 6021 CONNECTION DR IRVING, TX75039	DIRECT MAI		No	1,259,581	-1,259,581
	DIRECT PRINT COMMUNICATIONS 201 EAST SANDPOINTE SUITE 400 SANTA ANA, CA92707	DIRECT MAI		No	991,528	-991,528
	THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON, MA02421	DIRECT MAI		No	672,496	-672,496
	DONOR CARE CENTER INC 4345 STRAUSSSER ST NW NOTH CANTON, OH44720	TELEMARKET		No	245,058	-245,058
	BLACKBAUD 1800 DIAGONAL ROAD SUITE 400 ALEXANDRIA, VA22314	DIRECT MAI		No	101,502	-101,502


Total .................					10,064,173	-10,064,173

List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

All States

For Paperwork Reduction Act Notice, see the Instructions for Form 990or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990 or 990-EZ) 2013

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 NIKE WOMEN HALF (event type)	(b) Event #2 NIKE WOMENS MAR (event type)	(c) Other events 1,027 (total number)	(d) Total events (add col. (a) through col. (c))
1	Gross receipts . . .	4,339,846	8,884,317	177,639,059	190,863,222
2	Less: Contributions . .	3,606,608	6,946,142	153,037,578	163,590,328
3	Gross income (line 1 minus line 2) . . .	733,238	1,938,175	24,601,481	27,272,894
4	Cash prizes . . .
5	Noncash prizes . .
6	Rent/facility costs . .
7	Food and beverages .
8	Entertainment . . .
9	Other direct expenses .	733,238	1,938,175	24,601,481	27,272,894
10	Direct expense summary. Add lines 4 through 9 in column (d) ...........				27,272,894
11	Net income summary. Subtract line 10 from line 3, column (d)...........

Part III

Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

(a) Bingo

(b) Pull tabs/Instant
bingo/progressive bingo

(c) Other gaming

(d) Total gaming (add col.(a) through col.(c))

Gross revenue . . . .

795,990

Cash prizes . . . .

7,653

Non-cash prizes . . .

230,067

Rent/facility costs . . .

Other direct expenses . .

2,751

Volunteer labor . . .

	Yes %
	No

	Yes %
	No

	Yes71.000 %
	No

Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow

240,471

Net gaming income summary. Subtract line 7 from line 1, column (d) ......... right arrow

555,519

Enter the state(s) in which the organization operates gaming activities:

Is the organization licensed to operate gaming activities in each of these states? ............

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....

YesNo

If "Yes," explain:

Schedule G (Form 990 or 990-EZ) 2013

Page 3

Does the organization operate gaming activities with nonmembers? .................

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? ..........................

YesNo

Indicate the percentage of gaming activity operated in:

The organization's facility ......................

13a

25.000 %

An outside facility ........................

13b

75.000 %

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

ROSEMARIE LOFFREDO

Address

1311 MAMARONECK AVENUE
WHITE PLAINS,NY10605

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? ......................................

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

SEE SCHEDULE G PART IV

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? ............................

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v), and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also complete this part to provide any additional information (see instructions).

Return Reference

Explanation

SCHEDULE G, PART IV

SCHEDULE G PART I, LINE 2B LLS USED INFOCISION, MAIL AMERICA COMMUNICATIONS, DONOR CARE CENTER INC., EPSILON AND THOMPSON, HABIB & DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 19,483,579 DURING FISCAL YEAR 2014. LLS USED DIRECT PRINT COMMUNICATIONS, PARADYZ MATERA AND BLACKBAUD FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2014. SCHEDULE G, PART III, LINE 9 - STATES WITH GAMING OPERATIONS ARIZONA, DISTRICT OF COLUMBIA, IOWA, KANSAS, LOUISIANA, MICHIGAN, NEVADA, NEW YORK, OHIO, OREGON, PENNSYLVANIA, RHODE ISLAND, TEXAS, WISCONSIN. SCHEDULE G, PART III, LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF.

Schedule G (Form 990 or 990-EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990
lBullet

Information about Schedule I (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

Name of the organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number
13-5644916

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(f) Method of valuation (book, FMV, appraisal, other)	(h) Purpose of grant or assistance
(1) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	200,000	ACCRUAL	RESEARCH GRANT
(2) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	200,000	ACCRUAL	RESEARCH GRANT
(3) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	110,000	ACCRUAL	RESEARCH GRANT
(4) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	200,000	ACCRUAL	RESEARCH GRANT
(5) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	110,000	ACCRUAL	RESEARCH GRANT
(6) BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON,TX77030	74-1613878	3	200,000	ACCRUAL	RESEARCH GRANT
(7) BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON,TX77030	74-1613878	3	1,250,000	ACCRUAL	RESEARCH GRANT
(8) BECKMAN RESEARCH INSTITUTE OF THE C 1500 EAST DUARTE RD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(9) BECKMAN RESEARCH INSTITUTE OF THE C 1500 EAST DUARTE RD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(10) BECKMAN RESEARCH INSTITUTE OF THE C 1500 EAST DUARTE RD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(11) BETH ISRAEL DEACONESS MEDICAL CENTE 330 BROOKLINE AVENUE BOSTON,MA02215	04-2103881	3	110,000	ACCRUAL	RESEARCH GRANT
(12) BETH ISRAEL DEACONESS MEDICAL CENTE 330 BROOKLINE AVENUE BOSTON,MA02215	04-2103881	3	55,000	ACCRUAL	RESEARCH GRANT
(13) BETH ISRAEL DEACONESS MEDICAL CENTE 330 BROOKLINE AVENUE BOSTON,MA02215	04-2103881	3	200,000	ACCRUAL	RESEARCH GRANT
(14) BOARD OF REGENTS OF THE UNIVERSITY 4400 EMILE ST OMAHA,NE68198	47-0049123	3	200,000	ACCRUAL	RESEARCH GRANT
(15) BRANDEIS UNIVERSITY 415 SOUTH ST WALTHAM,MA02453	04-2103552	3	55,000	ACCRUAL	RESEARCH GRANT
(16) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON,MA02115	04-2312909	3	190,657	ACCRUAL	RESEARCH GRANT
(17) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON,MA02115	04-2312909	3	110,000	ACCRUAL	RESEARCH GRANT
(18) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON,MA02115	04-2312909	3	110,000	ACCRUAL	RESEARCH GRANT
(19) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON,MA02115	04-2312909	3	1,250,000	ACCRUAL	RESEARCH GRANT
(20) STANFORD UNIVERSITY MEDICAL CENTER 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	65,000	ACCRUAL	RESEARCH GRANT
(21) STANFORD UNIVERSITY MEDICAL CENTER 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	55,000	ACCRUAL	RESEARCH GRANT
(22) STANFORD UNIVERSITY MEDICAL CENTER 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	65,000	ACCRUAL	RESEARCH GRANT
(23) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(24) CA INSTITUTE OF TECHNOLOGY 1200 E CALIFORNIA BLVD PASADENA,CA91125	95-1643307	3	55,000	ACCRUAL	RESEARCH GRANT
(25) CA INSTITUTE OF TECHNOLOGY 1200 E CALIFORNIA BLVD PASADENA,CA91125	95-1643307	3	55,000	ACCRUAL	RESEARCH GRANT
(26) CASE WESTERN RESERVE UNIVERSITY - S 2109 ADELBERT RD CLEVELAND,OH44106	34-1018992	3	200,000	ACCRUAL	RESEARCH GRANT
(27) CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON,MA02115	04-2774441	3	55,000	ACCRUAL	RESEARCH GRANT
(28) CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON,MA02115	04-2774441	3	1,329,926	ACCRUAL	RESEARCH GRANT
(29) CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON,MA02115	04-2774441	3	65,000	ACCRUAL	RESEARCH GRANT
(30) CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON,MA02115	04-2774441	3	55,000	ACCRUAL	RESEARCH GRANT
(31) CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON,MA02115	04-2774441	3	55,000	ACCRUAL	RESEARCH GRANT
(32) CHILDREN'S HOSPITAL BOSTON AND HARV 300 LONGWOOD AVE BOSTON,MA02115	04-2774441	3	55,000	ACCRUAL	RESEARCH GRANT
(33) CHILDRENS HOSPITAL LOS ANGELES 4650 SUNSET BLVD LOS ANGELES,CA90027	95-1690977	3	200,000	ACCRUAL	RESEARCH GRANT
(34) CHILDRENS HOSPITAL MEDICAL CENTER-C 3333 BURNET AVE CINCINNATI,OH45229	31-0833936	3	110,000	ACCRUAL	RESEARCH GRANT
(35) CHILDRENS HOSPITAL MEDICAL CENTER-C 3333 BURNET AVE CINCINNATI,OH45229	31-0833936	3	200,000	ACCRUAL	RESEARCH GRANT
(36) CHILDREN'S HOSPITAL PHILADELPHIA 34TH STREET AND CIVIC CENTER BOULE PHILADELPHIA,PA19104	23-1352166	3	400,000	ACCRUAL	RESEARCH GRANT
(37) CINCINNATI CHILDREN'S HOSPITAL MEDI 3333 BURNET AVE CINCINNATI,OH45229	31-0833936	3	200,000	ACCRUAL	RESEARCH GRANT
(38) CINCINNATI CHILDREN'S HOSPITAL MEDI 3333 BURNET AVE CINCINNATI,OH45229	31-0833936	3	200,000	ACCRUAL	RESEARCH GRANT
(39) CLEVELAND CLINIC FOUNDATION 9200 EUCLID AVE CLEVELAND,OH44195	91-2153073	3	200,000	ACCRUAL	RESEARCH GRANT
(40) CLEVELAND CLINIC FOUNDATION 9200 EUCLID AVE CLEVELAND,OH44195	91-2153073	3	200,000	ACCRUAL	RESEARCH GRANT
(41) COLUMBIA UNIVERSITY 116TH ST BROADWAY NEW YORK,NY10027	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(42) COLUMBIA UNIVERSITY 615 WEST 131 STREET NEW YORK,NY10027	13-5598093	3	400,000	ACCRUAL	RESEARCH GRANT
(43) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	110,000	ACCRUAL	RESEARCH GRANT
(44) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	110,000	ACCRUAL	RESEARCH GRANT
(45) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(46) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(47) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(48) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(49) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(50) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(51) COLUMBIA UNIVERSITY MEDICAL CENTER 630 W 168TH STREET NEW YORK,NY10032	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(52) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(53) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(54) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	136,590	ACCRUAL	RESEARCH GRANT
(55) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	288,910	ACCRUAL	RESEARCH GRANT
(56) DANA FARBER CANCER INSTITUTE THE J 10 BROOKLINE PLACE WEST BROOKLINE,MA02445	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(57) DANA FARBER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	194,425	FMV	THERAPY ACCELERATION
(58) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(59) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(60) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(61) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(62) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(63) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	65,000	ACCRUAL	RESEARCH GRANT
(64) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	65,000	ACCRUAL	RESEARCH GRANT
(65) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(66) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(67) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(68) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(69) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(70) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(71) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(72) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(73) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(74) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(75) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(76) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(77) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(78) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(79) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(80) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(81) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(82) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(83) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	1,250,000	ACCRUAL	RESEARCH GRANT
(84) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	37,500	ACCRUAL	RESEARCH GRANT
(85) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(86) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(87) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON,MA02215	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(88) DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02215	04-2263040	3	400,000	ACCRUAL	RESEARCH GRANT
(89) DUKE UNIVERSITY MEDICAL CENTER 324 BLACKWELL STREET DURHAM,NC27708	56-0532129	3	382,081	ACCRUAL	RESEARCH GRANT
(90) EMORY UNIVERSITY 201 DOWMAN DR ATLANTA,GA30322	58-0566256	3	110,000	ACCRUAL	RESEARCH GRANT
(91) EMORY UNIVERSITY PO BOX 935084 ALTANTA,GA31193	58-0566256	3	450,000	FMV	THERAPY ACCELERATION
(92) FOX CHASE CANCER CENTER 333 COTTMAN AVE PHILADELPHIA,PA19111	23-2003072	3	200,000	ACCRUAL	RESEARCH GRANT
(93) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	65,000	ACCRUAL	RESEARCH GRANT
(94) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	55,000	ACCRUAL	RESEARCH GRANT
(95) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	55,000	ACCRUAL	RESEARCH GRANT
(96) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	200,000	ACCRUAL	RESEARCH GRANT
(97) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	200,000	ACCRUAL	RESEARCH GRANT
(98) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	100,000	ACCRUAL	RESEARCH GRANT
(99) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVE N SEATTLE,WA98109	23-7156071	3	110,000	ACCRUAL	RESEARCH GRANT
(100) GEORGIA CENTER FOR ONCOLOGY RESEARC 50 HURT PLAZA ALTANTA,GA30303	57-1159979	3	190,494	FMV	THERAPY ACCELERATION
(101) H LEE MOFFITT CANCER CENTER & RESE 12902 USF MAGNOLIA DR TAMPA,FL33612	59-3238636	3	65,000	ACCRUAL	RESEARCH GRANT
(102) HARVARD MEDICAL SCHOOL 25 SHATTUCK ST BOSTON,MA02115	04-2103580	3	65,000	ACCRUAL	RESEARCH GRANT
(103) HARVARD MEDICAL SCHOOL 25 SHATTUCK ST BOSTON,MA02115	04-2103580	3	55,000	ACCRUAL	RESEARCH GRANT
(104) HARVARD MEDICAL SCHOOL 25 SHATTUCK ST BOSTON,MA02115	04-2103580	3	55,000	ACCRUAL	RESEARCH GRANT
(105) HARVARD MEDICAL SCHOOL 25 SHATTUCK ST BOSTON,MA02115	04-2103580	3	55,000	ACCRUAL	RESEARCH GRANT
(106) ICAHN SCHOOL OF MEDICINE AT MOUNT S 1428 MADISON AVE NEW YORK,NY10029	13-6171197	3	110,000	ACCRUAL	RESEARCH GRANT
(107) IMMUNE DISEASE INSTITUTE (FKA) THE 3 BLACKFAN CIR BOSTON,MA02115	04-2103580	3	1,250,000	ACCRUAL	RESEARCH GRANT
(108) INDIANA UNIVERSITY 420 UNIVERSITY BLVD INDIANAPOLIS,IN46202	35-6001673	3	110,000	ACCRUAL	RESEARCH GRANT
(109) JOAN & SANFORD I WEILL CORNELL MED 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(110) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	110,000	ACCRUAL	RESEARCH GRANT
(111) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	55,000	ACCRUAL	RESEARCH GRANT
(112) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(113) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(114) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(115) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(116) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(117) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(118) JOAN & SANFORD I WEILL MEDICAL COL 1300 YORK AVE NEW YORK,NY10065	13-1623978	3	200,000	ACCRUAL	RESEARCH GRANT
(119) JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY BALTIMORE,MD21205	52-0595110	3	65,000	ACCRUAL	RESEARCH GRANT
(120) JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY BALTIMORE,MD21205	52-0595110	3	65,000	ACCRUAL	RESEARCH GRANT
(121) JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY BALTIMORE,MD21205	52-0595110	3	277,750	ACCRUAL	RESEARCH GRANT
(122) JOHNS HOPKINS UNIVERSITY CENTR 12529 COLLECTIONS CENTER DRIVE CHICAGO,IL60693	52-0595110	3	350,000	FMV	THERAPY ACCELERATION
(123) JOHNS HOPKINS UNIVERSITY CENTR 12529 COLLECTIONS CENTER DRIVE CHICAGO,IL60693	52-0595110	3	700,000	FMV	THERAPY ACCELERATION
(124) JOHNS HOPKINS UNIVERSITY SCHOOL OF 733 N BROADWAY BALTIMORE,MD21205	52-0595110	3	110,000	ACCRUAL	RESEARCH GRANT
(125) JOHNS HOPKINS UNIVERSITY SCHOOL OF 733 N BROADWAY BALTIMORE,MD21205	52-0595110	3	110,000	ACCRUAL	RESEARCH GRANT
(126) JOHNS HOPKINS UNIVERSITY SCHOOL OF 733 N BROADWAY BALTIMORE,MD21205	52-0595110	3	200,000	ACCRUAL	RESEARCH GRANT
(127) JOHNS HOPKINS UNIVERSITY SCHOOL OF 733 N BROADWAY BALTIMORE,MD21205	52-0595110	3	200,000	ACCRUAL	RESEARCH GRANT
(128) LA JOLLA INSTITUTE FOR ALLERGY AND 9420 ATHENA CIR LA JOLLA,CA92037	33-0328688	3	200,000	ACCRUAL	RESEARCH GRANT
(129) LUDWIG INSTITUTE FOR CANCER RESEARC 666 THIRD AVE 28TH FL NEW YORK,NY10017	23-7121131	3	55,000	ACCRUAL	RESEARCH GRANT
(130) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON,MA02114	04-1564655	3	65,000	ACCRUAL	RESEARCH GRANT
(131) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON,MA02114	04-1564655	3	110,000	ACCRUAL	RESEARCH GRANT
(132) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON,MA02114	04-1564655	3	65,000	ACCRUAL	RESEARCH GRANT
(133) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON,MA02114	04-1564655	3	200,000	ACCRUAL	RESEARCH GRANT
(134) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON,MA02114	04-1564655	3	110,000	ACCRUAL	RESEARCH GRANT
(135) MASSACHUSETTS INSTITUTE OF TECHNOLO 77 MASSACHUSETTS AVE CAMBRIDGE,MA02139	04-2103594	3	55,000	ACCRUAL	RESEARCH GRANT
(136) MASSACHUSSETS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-1564655	3	356,484	ACCRUAL	RESEARCH GRANT
(137) MAYO CLINIC ARIZONA 13400 E SHEA BLVD SCOTTSDALE,AZ85259	41-6011702	3	200,000	ACCRUAL	RESEARCH GRANT
(138) MAYO CLINIC ARIZONA 13400 E SHEA BLVD SCOTTSDALE,AZ85259	41-6011702	3	110,000	ACCRUAL	RESEARCH GRANT
(139) MAYO CLINIC ARIZONA DBA MAYO CLI 13400 E SHEA BLVD SCOTTSDALE,AZ85259	41-6011702	3	200,000	ACCRUAL	RESEARCH GRANT
(140) MAYO CLINIC ARIZONA DBA MAYO CLI 13400 E SHEA BLVD SCOTTSDALE,AZ85259	41-6011702	3	200,000	ACCRUAL	RESEARCH GRANT
(141) MAYO CLINIC ARIZONA 13400 E SHEA BLVD SCOTTSDALE,AZ85259	41-6011702	3	110,000	ACCRUAL	RESEARCH GRANT
(142) MAYO CLINIC ARIZONA 13400 E SHEA BLVD SCOTTSDALE,AZ85259	41-6011702	3	200,000	ACCRUAL	RESEARCH GRANT
(143) MEMORIAL SLOAN KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	110,000	ACCRUAL	RESEARCH GRANT
(144) MEMORIAL SLOAN KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	65,000	ACCRUAL	RESEARCH GRANT
(145) MEMORIAL SLOAN KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	55,000	ACCRUAL	RESEARCH GRANT
(146) MEMORIAL SLOAN KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	55,000	ACCRUAL	RESEARCH GRANT
(147) MEMORIAL SLOAN-KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	110,000	ACCRUAL	RESEARCH GRANT
(148) MEMORIAL SLOAN-KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	200,000	ACCRUAL	RESEARCH GRANT
(149) MEMORIAL SLOAN-KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	200,000	ACCRUAL	RESEARCH GRANT
(150) MEMORIAL SLOAN-KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	200,000	ACCRUAL	RESEARCH GRANT
(151) MOFFITT CANCER CENTER AND RESEARCH 12902 USF MAGNOLIA DR TAMPA,FL33612	59-3238636	3	200,000	ACCRUAL	RESEARCH GRANT
(152) MOUNT SINAI SCHOOL OF MEDICINE 1428 MADISON AVE NEW YORK,NY10029	13-6171197	3	110,000	ACCRUAL	RESEARCH GRANT
(153) MOUNT SINAI SCHOOL OF MEDICINE 1428 MADISON AVE NEW YORK,NY10029	13-6171197	3	200,000	ACCRUAL	RESEARCH GRANT
(154) MPN RESEARCH FOUNDATION 180 N MICHIGAN AVENUE SUITE 1870 CHICAGO,IL60601	36-4330967	3	400,000	ACCRUAL	RESEARCH GRANT
(155) NEW YORK UNIVERSITY SCHOOL OF MEDIC 550 1ST AVENUE NEW YORK,NY10016	13-5562308	3	110,000	ACCRUAL	RESEARCH GRANT
(156) NEW YORK UNIVERSITY SCHOOL OF MEDIC 550 1ST AVENUE NEW YORK,NY10016	13-5562308	3	65,000	ACCRUAL	RESEARCH GRANT
(157) NEW YORK UNIVERSITY SCHOOL OF MEDIC 550 1ST AVENUE NEW YORK,NY10016	13-5562308	3	1,250,000	ACCRUAL	RESEARCH GRANT
(158) NEW YORK UNIVERSITY SCHOOL OF MEDIC 550 1ST AVENUE NEW YORK,NY10016	13-5562308	3	65,000	ACCRUAL	RESEARCH GRANT
(159) NEW YORK UNIVERSITY SCHOOL OF MEDIC 550 FIRST AVE GBH-SC1-47 NEW YORK,NY10016	13-5562308	3	100,000	FMV	THERAPY ACCELERATION
(160) NORTHWESTERN UNIVERSITY 633 CLARK ST EVANSTON,IL60208	36-2167817	3	297,404	ACCRUAL	RESEARCH GRANT
(161) NORTHWESTERN UNIVERSITY - CHICAGO C 750 N LAKE SHORE DR CHICAGO,IL60611	36-2167817	3	55,000	ACCRUAL	RESEARCH GRANT
(162) NORTHWESTERN UNIVERSITY - CHICAGO C 750 N LAKE SHORE DR CHICAGO,IL60611	36-2167817	3	200,000	ACCRUAL	RESEARCH GRANT
(163) NORTHWESTERN UNIVERSITY - CHICAGO C 750 N LAKE SHORE DR CHICAGO,IL60611	36-2167817	3	200,000	ACCRUAL	RESEARCH GRANT
(164) NORTHWESTERN UNIVERSITY - CHICAGO C 750 N LAKE SHORE DR CHICAGO,IL60611	36-2167817	3	200,000	ACCRUAL	RESEARCH GRANT
(165) NORTHWESTERN UNIVERSITY - CHICAGO C 750 N LAKE SHORE DR CHICAGO,IL60611	36-2167817	3	1,250,000	ACCRUAL	RESEARCH GRANT
(166) OHIO STATE UNIVERSITY 281 W LANE AVE COLUMBUS,OH43210	31-6025986	3	300,000	ACCRUAL	RESEARCH GRANT
(167) OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND,OR97239	93-1176109	3	55,000	ACCRUAL	RESEARCH GRANT
(168) OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND,OR97239	93-1176109	3	1,250,000	ACCRUAL	RESEARCH GRANT
(169) OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT ST PORTLAND,OR97239	93-1176109	3	555,500	FMV	THERAPY ACCELERATION
(170) OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT ST PORTLAND,OR97239	93-1176109	3	1,111,000	FMV	THERAPY ACCELERATION
(171) PRESIDENT & FELLOWS OF HARVARD COLL MASSACHUSETTS HALL CAMBRIDGE,MA02138	04-2103580	3	200,000	ACCRUAL	RESEARCH GRANT
(172) PRESIDENT & FELLOWS OF HARVARD COLL MASSACHUSETTS HALL CAMBRIDGE,MA02138	04-2103580	3	65,000	ACCRUAL	RESEARCH GRANT
(173) PRESIDENT & FELLOWS OF HARVARD COLL MASSACHUSETTS HALL CAMBRIDGE,MA02138	04-2103580	3	55,000	ACCRUAL	RESEARCH GRANT
(174) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	20,059	FMV	THERAPY ACCELERATION
(175) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	168,259	FMV	THERAPY ACCELERATION
(176) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	26,587	FMV	THERAPY ACCELERATION
(177) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	13,012	FMV	THERAPY ACCELERATION
(178) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	286,084	FMV	THERAPY ACCELERATION
(179) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	260,211	FMV	THERAPY ACCELERATION
(180) REGENTS OF THE UNIVERSITY OF MICHI BOX 223131 PITTSBURGH,PA15251	38-6006309	3	217,067	FMV	THERAPY ACCELERATION
(181) REGENTS OF THE UNIVERSITY OF MINNES 420 JOHH JOHNSTON HALL 101 PLEASA MINNEAPOLIS,MN55455	41-6007513	3	200,000	ACCRUAL	RESEARCH GRANT
(182) REGENTS OF THE UNIVERSITY OF MINNES 420 JOHH JOHNSTON HALL 101 PLEASA MINNEAPOLIS,MN55455	41-6007513	3	100,000	ACCRUAL	RESEARCH GRANT
(183) RHODE ISLAND HOSPITAL 593 EDDY ST PROVIDENCE,RI02903	05-0258954	3	65,000	ACCRUAL	RESEARCH GRANT
(184) SAINT LOUIS UNIVERSITY 221 N GRAND BLVD ST LOUIS,MO63103	43-0654872	3	200,000	ACCRUAL	RESEARCH GRANT
(185) SLOAN KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	55,000	ACCRUAL	RESEARCH GRANT
(186) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	110,000	ACCRUAL	RESEARCH GRANT
(187) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	500,000	ACCRUAL	RESEARCH GRANT
(188) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	200,000	ACCRUAL	RESEARCH GRANT
(189) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	110,000	ACCRUAL	RESEARCH GRANT
(190) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	110,000	ACCRUAL	RESEARCH GRANT
(191) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	110,000	ACCRUAL	RESEARCH GRANT
(192) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	65,000	ACCRUAL	RESEARCH GRANT
(193) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	55,000	ACCRUAL	RESEARCH GRANT
(194) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NEW YORK,NY10065	13-1924236	3	55,000	ACCRUAL	RESEARCH GRANT
(195) ST JUDE CHILDREN'S RESEARCH HOSPIT 262 DANNY THOMAS PL MEMPHIS,TN38105	62-0646012	3	65,000	ACCRUAL	RESEARCH GRANT
(196) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	65,000	ACCRUAL	RESEARCH GRANT
(197) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	55,000	ACCRUAL	RESEARCH GRANT
(198) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	500,000	ACCRUAL	RESEARCH GRANT
(199) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	65,000	ACCRUAL	RESEARCH GRANT
(200) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	65,000	ACCRUAL	RESEARCH GRANT
(201) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	55,000	ACCRUAL	RESEARCH GRANT
(202) STANFORD UNIVERSITY 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	55,000	ACCRUAL	RESEARCH GRANT
(203) STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO,CA94144	94-1156365	3	326,076	FMV	THERAPY ACCELERATION
(204) STOWERS INSTITUTE FOR MEDICAL RESEA 1000 E 50TH ST KANSAS CITY,MO64110	20-2993509	3	55,000	ACCRUAL	RESEARCH GRANT
(205) SUNY UPSTATE MEDICAL UNIVERSITY 750 E ADAMS ST SYRACUSE,NY13210	16-6038703	3	110,000	ACCRUAL	RESEARCH GRANT
(206) THE BOARD OF REGENTS OF THE UNIVERS 1860 VAN HISE HALL 1220 LINDEN DR MADISON,WI53706	39-6006492	3	215,000	ACCRUAL	RESEARCH GRANT
(207) THE BOARD OF TRUSTEES OF THE LELAND 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	268,353	ACCRUAL	RESEARCH GRANT
(208) THE BOARD OF TRUSTEES OF THE LELAND 291 CAMPUS DR STANFORD,CA94305	94-1156365	3	110,000	ACCRUAL	RESEARCH GRANT
(209) THE BOARD OF TRUSTEES OF THE UNIVER 700 S HALSTED ST 2029 CHICAGO,IL60607	36-2177139	3	110,000	ACCRUAL	RESEARCH GRANT
(210) THE CHILDREN'S HOSPITAL OF PHILADEL 34TH ST CIVIC CENTER BLVD PHILADELPHIA,PA19104	23-2237932	3	110,000	ACCRUAL	RESEARCH GRANT
(211) THE CHILDREN'S HOSPITAL OF PHILADEL 34TH ST CIVIC CENTER BLVD PHILADELPHIA,PA19104	23-2237932	3	110,000	ACCRUAL	RESEARCH GRANT
(212) THE HOSPITAL FOR SPECIAL SURGERY 535 E 70TH ST NEW YORK,NY10021	13-6714749	3	200,000	ACCRUAL	RESEARCH GRANT
(213) THE J DAVID GLADSTONE INSTITUTES 88 KEARNY ST SUITE 900 SAN FRANCISCO,CA94108	23-7203666	3	100,000	ACCRUAL	RESEARCH GRANT
(214) THE OHIO STATE UNIVERSITY 281 W LANE AVE COLUMBUS,OH43210	31-6025986	3	65,000	ACCRUAL	RESEARCH GRANT
(215) THE OHIO STATE UNIVERSITY 281 W LANE AVE COLUMBUS,OH43210	31-6025986	3	55,000	ACCRUAL	RESEARCH GRANT
(216) THE OHIO STATE UNIVERSITY 281 W LANE AVE COLUMBUS,OH43210	31-6025986	3	1,250,000	ACCRUAL	RESEARCH GRANT
(217) THE OHIO STATE UNIVERSITY RESEARCH 281 W LANE AVE COLUMBUS,OH43210	31-6025986	3	200,000	ACCRUAL	RESEARCH GRANT
(218) THE PENNSYLVANIA STATE UNIVERSITY C 500 UNIVERSITY DRIVE HERSHEY,PA17033	24-6000376	3	200,000	ACCRUAL	RESEARCH GRANT
(219) THE REGENTS OF THE UNIVERSITY OF CA 2150 SHATTUCK AVE SUITE 300 BERKELEY,CA94704	94-6002123	3	65,000	ACCRUAL	RESEARCH GRANT
(220) THE REGENTS OF THE UNIVERSITY OF CA 2150 SHATTUCK AVE SUITE 300 BERKELEY,CA94704	94-6002123	3	65,000	ACCRUAL	RESEARCH GRANT
(221) THE REGENTS OF THE UNIVERSITY OF CA 2150 SHATTUCK AVE SUITE 300 BERKELEY,CA94704	94-6002123	3	55,000	ACCRUAL	RESEARCH GRANT
(222) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVE SUITE 211 LOS ANGELES,CA90095	95-6006143	3	65,000	ACCRUAL	RESEARCH GRANT
(223) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVE SUITE 211 LOS ANGELES,CA90095	95-6006143	3	55,000	ACCRUAL	RESEARCH GRANT
(224) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVE SUITE 211 LOS ANGELES,CA90095	95-6006143	3	200,000	ACCRUAL	RESEARCH GRANT
(225) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	110,000	ACCRUAL	RESEARCH GRANT
(226) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	110,000	ACCRUAL	RESEARCH GRANT
(227) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	110,000	ACCRUAL	RESEARCH GRANT
(228) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	55,000	ACCRUAL	RESEARCH GRANT
(229) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	1,250,000	ACCRUAL	RESEARCH GRANT
(230) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	55,000	ACCRUAL	RESEARCH GRANT
(231) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(232) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	65,000	ACCRUAL	RESEARCH GRANT
(233) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(234) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(235) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(236) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(237) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(238) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(239) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	65,000	ACCRUAL	RESEARCH GRANT
(240) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(241) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(242) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(243) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(244) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(245) THE REGENTS OF THE UNIVERSITY OF CA 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(246) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DR LA JOLLA,CA92093	95-6006144	3	398,316	ACCRUAL	RESEARCH GRANT
(247) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVE SUITE 211 LOS ANGELES,CA90095	95-6006143	3	110,000	ACCRUAL	RESEARCH GRANT
(248) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(249) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(250) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(251) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(252) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(253) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(254) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(255) THE REGENTS OF THE UNIVERSITY OF MI 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(256) THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK,NY10065	13-1624158	3	65,000	ACCRUAL	RESEARCH GRANT
(257) THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(258) THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(259) THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(260) THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(261) THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(262) THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA,CA92037	33-0435954	3	110,000	ACCRUAL	RESEARCH GRANT
(263) THE TRUSTEES OF THE UNIVERSITY OF P 1 COLLEGE HALL ROOM 211 PHILADELPHIA,PA19104	23-1352685	3	55,000	ACCRUAL	RESEARCH GRANT
(264) THE TRUSTEES OF THE UNIVERSITY OF P 1 COLLEGE HALL ROOM 211 PHILADELPHIA,PA19104	23-1352685	3	65,000	ACCRUAL	RESEARCH GRANT
(265) THE TRUSTEES OF THE UNIVERSITY OF P 1 COLLEGE HALL ROOM 211 PHILADELPHIA,PA19104	23-1352685	3	55,000	ACCRUAL	RESEARCH GRANT
(266) THE TRUSTEES OF THE UNIVERSITY OF P 1 COLLEGE HALL ROOM 211 PHILADELPHIA,PA19104	23-1352685	3	200,000	ACCRUAL	RESEARCH GRANT
(267) THE TRUSTEES OF THE UNIVERSITY OF P 1 COLLEGE HALL ROOM 211 PHILADELPHIA,PA19104	23-1352685	3	55,000	ACCRUAL	RESEARCH GRANT
(268) THE TRUSTEES OF THE UNIVERSITY OF P 1 COLLEGE HALL ROOM 211 PHILADELPHIA,PA19104	23-1352685	3	1,250,000	ACCRUAL	RESEARCH GRANT
(269) THE UNIVERSITY OF ALABAMA AT BIRMIN 1720 2ND AVE S BIRMINGHAM,AL35233	63-6005396	3	110,000	ACCRUAL	RESEARCH GRANT
(270) THE UNIVERSITY OF CHICAGO 5801 S ELLIS AVENUE CHICAGO,IL60637	36-2177139	3	200,000	ACCRUAL	RESEARCH GRANT
(271) THE UNIVERSITY OF CHICAGO 5801 S ELLIS AVENUE CHICAGO,IL60637	36-2177139	3	200,000	ACCRUAL	RESEARCH GRANT
(272) THE UNIVERSITY OF NORTH CAROLINA AT CB 1350 104 AIRPORT DR SUITE 220 CHAPEL HILL,NC27599	56-6001393	3	200,000	ACCRUAL	RESEARCH GRANT
(273) THE UNIVERSITY OF NORTH CAROLINA AT 104 AIRPORT DRIVE CHAPEL HILL,NC27599	56-6001393	3	397,026	ACCRUAL	RESEARCH GRANT
(274) THE UNIVERSITY OF TEXAS MD ANDERSON 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	200,000	ACCRUAL	RESEARCH GRANT
(275) THE UNIVERSITY OF TEXAS MD ANDERSON 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	200,000	ACCRUAL	RESEARCH GRANT
(276) TRUSTEES OF DARTMOUTH COLLEGE 6010 PARKHURST HALL SUITE 204 HANOVER,NH03755	02-0222111	3	200,000	ACCRUAL	RESEARCH GRANT
(277) TUFTS MEDICAL CENTER 800 WASHINGTON ST BOSTON,MA02111	04-3400617	3	300,000	ACCRUAL	RESEARCH GRANT
(278) UNIV OF TEXAS HEALTH SCIENCE CENTER 7703 FLOYD CURL DR SAN ANTONIO,TX78229	74-1586031	3	200,000	ACCRUAL	RESEARCH GRANT
(279) UNIVERSITY OF ARKANSAS FOR MEDICAL 4301 WEST MARKHAM LITTLE ROCK,AR72205	71-0236904	3	200,000	ACCRUAL	RESEARCH GRANT
(280) UNIVERSITY OF CA SAN DIEGO - HEALT 9500 GILMAN DR DEPT 0012 LA JOLLA,CA92093	95-6006144	3	55,000	ACCRUAL	RESEARCH GRANT
(281) UNIVERSITY OF CALIFORNIA SAN FRANCI 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(282) UNIVERSITY OF CALIFORNIA SAN FRANCI 500 PARNASSUS AVE SAN FRANCISCO,CA94143	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(283) UNIVERSITY OF COLORADO AT BOULDER SPONSORED PROJECT ACCOUNTING PO BO DENVER,CO80291	84-6000555	3	55,000	ACCRUAL	RESEARCH GRANT
(284) UNIVERSITY OF CONNECTICUT HEALTH CE 263 FARMINGTON AVEUE FARMINGTON,CT06032	06-0772160	3	326,189	ACCRUAL	RESEARCH GRANT
(285) UNIVERSITY OF FLORIDA GRINTER HALL PO BOX 115500 GAINESVILLE,FL32611	59-6002052	3	110,000	ACCRUAL	RESEARCH GRANT
(286) UNIVERSITY OF FLORIDA GRINTER HALL PO BOX 115500 GAINESVILLE,FL32611	59-6002052	3	200,000	ACCRUAL	RESEARCH GRANT
(287) UNIVERSITY OF FLORIDA 219 GINTER HAL GAINESVILLE,FL32611	59-6002052	3	394,882	ACCRUAL	RESEARCH GRANT
(288) UNIVERSITY OF KANSAS MEDICAL CENTER 4350 SHAWNEE MISSION PARKWAY FAIRWAY,KS66205	48-1202402	3	84,948	FMV	THERAPY ACCELERATION
(289) UNIVERSITY OF MARYLAND BALTIMORE 620 W LEXINGTON ST BALTIMORE,MD21201	52-6002033	3	200,000	ACCRUAL	RESEARCH GRANT
(290) UNIVERSITY OF MASSACHUSETTS MEDICAL 55 N LAKE AVENUE WORCESTER,MA01655	04-3167352	3	110,000	ACCRUAL	RESEARCH GRANT
(291) UNIVERSITY OF MASSACHUSETTS MEDICAL 55 N LAKE AVENUE WORCESTER,MA01655	04-3167352	3	55,000	ACCRUAL	RESEARCH GRANT
(292) UNIVERSITY OF MASSACHUSETTS MEDICAL 55 N LAKE AVENUE WORCESTER,MA01655	04-3167352	3	200,000	ACCRUAL	RESEARCH GRANT
(293) UNIVERSITY OF MASSACHUSETTS MEDICAL 55 N LAKE AVENUE WORCESTER,MA01655	04-3167352	3	110,000	ACCRUAL	RESEARCH GRANT
(294) UNIVERSITY OF MASSACHUSETTS MEDICAL 55 N LAKE AVENUE WORCESTER,MA01655	04-3167352	3	55,000	ACCRUAL	RESEARCH GRANT
(295) UNIVERSITY OF MICHIGAN 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	241,290	ACCRUAL	RESEARCH GRANT
(296) UNIVERSITY OF MICHIGAN DEPARTMENT O 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(297) UNIVERSITY OF MICHIGAN DEPARTMENT O 500 S STATE ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(298) UNIVERSITY OF MINNESOTA - TWIN CITI 420 JOHH JOHNSTON HALL 101 PLEASA MINNEAPOLIS,MN55455	41-6007513	3	110,000	ACCRUAL	RESEARCH GRANT
(299) UNIVERSITY OF MINNESOTA TWIN CITIE 420 JOHH JOHNSTON HALL 101 PLEASA MINNEAPOLIS,MN55455	41-6007513	3	200,000	ACCRUAL	RESEARCH GRANT
(300) UNIVERSITY OF NORTH CAROLINA AT CHA CB 1350 104 AIRPORT DR SUITE 220 CHAPEL HILL,NC27599	56-6001393	3	55,000	ACCRUAL	RESEARCH GRANT
(301) UNIVERSITY OF ROCHESTER 515 HYLAN BUILDING RC BOX 270140 ROCHESTER,NY14627	16-0743209	3	200,000	ACCRUAL	RESEARCH GRANT
(302) UNIVERSITY OF TEXAS MD ANDERSON C 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	200,000	ACCRUAL	RESEARCH GRANT
(303) UNIVERSITY OF TEXAS MD ANDERSON C 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	500,000	ACCRUAL	RESEARCH GRANT
(304) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	110,000	ACCRUAL	RESEARCH GRANT
(305) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	110,000	ACCRUAL	RESEARCH GRANT
(306) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	110,000	ACCRUAL	RESEARCH GRANT
(307) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	110,000	ACCRUAL	RESEARCH GRANT
(308) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	400,000	ACCRUAL	RESEARCH GRANT
(309) UNIVERSITY OF UTAH 201 PRESIDENTS CIR SALT LAKE CITY,UT84112	87-6000525	3	200,000	ACCRUAL	RESEARCH GRANT
(310) UNIVERSITY OF UTAH 201 PRESIDENTS CIR SALT LAKE CITY,UT84112	87-6000525	3	111,715	ACCRUAL	RESEARCH GRANT
(311) UNIVERSITY OF UTAH 201 PRESIDENTS CIR SALT LAKE CITY,UT84112	87-6000525	3	65,000	ACCRUAL	RESEARCH GRANT
(312) UNIVERSITY OF VIRGINIA UNIVERSITY OF VIRGINIA SCHOOL OF ME CHARLOTTESVILE,VA22908	54-1682176	3	100,000	ACCRUAL	RESEARCH GRANT
(313) UNIVERSITY OF VIRGINIA UNIVERSITY OF VIRGINIA SCHOOL OF ME CHARLOTTESVILE,VA22908	54-1682176	3	100,000	ACCRUAL	RESEARCH GRANT
(314) UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE 17TH FL UW TOWE SEATTLE,WA98105	94-3079432	3	55,000	ACCRUAL	RESEARCH GRANT
(315) UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE 17TH FL UW TOWE SEATTLE,WA98105	94-3079432	3	200,000	ACCRUAL	RESEARCH GRANT
(316) UNIVERSITY OF WISCONSIN-MADISON 21 N PARK ST SUITE 6401 MADISON,WI53715	39-6006492	3	110,000	ACCRUAL	RESEARCH GRANT
(317) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	75-6002868	3	110,000	ACCRUAL	RESEARCH GRANT
(318) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	75-6002868	3	110,000	ACCRUAL	RESEARCH GRANT
(319) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	75-6002868	3	55,000	ACCRUAL	RESEARCH GRANT
(320) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	75-6002868	3	200,000	ACCRUAL	RESEARCH GRANT
(321) VANDERBILT UNIVERSITY MEDICAL CENTE 1211 MEDICAL CENTER DR NASHVILLE,TN37232	62-0476822	3	110,000	ACCRUAL	RESEARCH GRANT
(322) VIRGINIA COMMONWEALTH UNIVERSITY 821 W FRANKLIN ST RICHMOND,VA23284	54-6001758	3	200,000	ACCRUAL	RESEARCH GRANT
(323) WAKE FOREST UNIVERSITY HEALTH SCIEN 1 MEDICAL CENTER BLVD WINSTONSALEM,NC27103	22-3849199	3	200,000	ACCRUAL	RESEARCH GRANT
(324) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DR ST LOUIS,MO63130	43-0653611	3	200,000	ACCRUAL	RESEARCH GRANT
(325) WASHINGTON UNIVERSITY OF ST LOUIS 660 S EUCLID AVE ST LOUIS,MO63110	43-0653611	3	110,000	ACCRUAL	RESEARCH GRANT
(326) WASHINGTON UNIVESITY SCHOOL OF MEDI 660 EUCLID AVEUNE ST LOUIS,MO63110	91-6001537	3	399,033	ACCRUAL	RESEARCH GRANT
(327) WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE,MA02142	06-1043412	3	110,000	ACCRUAL	RESEARCH GRANT
(328) WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE,MA02142	06-1043412	3	65,000	ACCRUAL	RESEARCH GRANT
(329) WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE,MA02142	06-1043412	3	55,000	ACCRUAL	RESEARCH GRANT
(330) YALE UNIVERSITY 47 COLLEGE ST SUITE 216 NEW HAVEN,CT06510	06-0646973	3	55,000	ACCRUAL	RESEARCH GRANT
(331) YALE UNIVERSITY 47 COLLEGE ST SUITE 216 NEW HAVEN,CT06510	06-0646973	3	55,000	ACCRUAL	RESEARCH GRANT
(332) YALE UNIVERSITY 47 COLLEGE ST SUITE 216 NEW HAVEN,CT06510	06-0646973	3	100,000	ACCRUAL	RESEARCH GRANT
(333) YALE UNIVERSITY 47 COLLEGE ST SUITE 216 NEW HAVEN,CT06510	06-0646973	3	55,000	ACCRUAL	RESEARCH GRANT
(334) ACETYLON SEAPORT CENTER 70 FARGO CENTER BOSTON,MA02210	26-3506788		250,000	FMV	THERAPY ACCELERATION
(335) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		44,891	FMV	THERAPY ACCELERATION
(336) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		11,053	FMV	THERAPY ACCELERATION
(337) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		17,505	FMV	THERAPY ACCELERATION
(338) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		10,392	FMV	THERAPY ACCELERATION
(339) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		16,427	FMV	THERAPY ACCELERATION
(340) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		25,000	FMV	THERAPY ACCELERATION
(341) BECKLOFF ASSOCIATES INC 3203 EAST SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		100,000	FMV	THERAPY ACCELERATION
(342) BIO THERYX INC 20 CABIN RIDGE RD CHAPPAQUA,NY10514	26-0501342		250,000	FMV	THERAPY ACCELERATION
(343) CELATOR PHARMACEUTICALS INC 200 PRINCETON SOUTH CORPORATE CENTE EWING,NJ08628	20-2680869		267,145	FMV	THERAPY ACCELERATION
(344) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		36,053	FMV	THERAPY ACCELERATION
(345) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		42,750	FMV	THERAPY ACCELERATION
(346) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		72,050	FMV	THERAPY ACCELERATION
(347) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		20,816	FMV	THERAPY ACCELERATION
(348) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		6,210	FMV	THERAPY ACCELERATION
(349) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		12,820	FMV	THERAPY ACCELERATION
(350) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		13,877	FMV	THERAPY ACCELERATION
(351) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		35,658	FMV	THERAPY ACCELERATION
(352) CHARLES RIVER LABORATORIES INC GPO BOX 27812 NEW YORK,NY10087	76-0509980		614,490	FMV	THERAPY ACCELERATION
(353) CONSTELLATION PHARMACEUTICALS 215 FIRST STREET CAMBRIDGE,MA02142	26-1741721		1,000,000	FMV	THERAPY ACCELERATION
(354) CONSTELLATION PHARMACEUTICALS 215 FIRST STREET CAMBRIDGE,MA02142	26-1741721		250,000	FMV	THERAPY ACCELERATION
(355) CONSTELLATION PHARMACEUTICALS 215 FIRST STREET CAMBRIDGE,MA02142	26-1741721		1,500,000	FMV	THERAPY ACCELERATION
(356) KP PHARMACEUTICAL TECHNOLOGY 1212 W RAPPEL AVE BLOOMINGTON,IN47404	35-2025958		20,588	FMV	THERAPY ACCELERATION
(357) NANOSYN INC 3100 CENTRAL EXPRESSWAY SANTA CLARA,CA95051	86-0909295		1,064,250	FMV	THERAPY ACCELERATION
(358) NANOSYN INC 3100 CENTRAL EXPRESSWAY SANTA CLARA,CA95051	86-0909295		455,740	FMV	THERAPY ACCELERATION
(359) SHAPE PHARMACEUTICALS INC 47 THORNDIKE STREET CAMBRIDGE,MA02141	26-3714475		300,000	FMV	THERAPY ACCELERATION
(360) SHAPE PHARMACEUTICALS INC 47 THORNDIKE STREET CAMBRIDGE,MA02141	26-3714475		241,000	FMV	THERAPY ACCELERATION
(361) STEMLINE THERAPEUTICS INC 750 LEXINGTON AVE NEW YORK,NY10022	45-0522567		1,000,000	FMV	THERAPY ACCELERATION
(362) VALOR BIOTHERAPEUTICS 8800 HSC PARKWAY BRYAN,TX77807	46-1883738		400,000	FMV	THERAPY ACCELERATION
(363) VALOR BIOTHERAPEUTICS 8800 HSC PARKWAY BRYAN,TX77807	46-1883738		400,000	FMV	THERAPY ACCELERATION
(364) VELESCO PHARMACEUTICAL SERVICE 46701 N COMMERCE CENTER DRIVE PLYMOUTH,MI48170	26-1330932		20,160	FMV	THERAPY ACCELERATION

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................ Bullet Image

109

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2013

Page 2

Part III

Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant
(1) PATIENT FINANCIAL AID	25236	2,523,615
(2) COPAY ASSISTANCE CLL	2120	4,453,691
(3) COPAY ASSISTANCE LYMPHOMA	7905	17,443,678
(4) COPAY ASSISTANCE MDS	1478	3,320,299
(5) COPAY ASSISTANCE MYELOMA	6976	23,593,351
(6) COPAY ASSISTANCE MANTEL	161	435,000
(7) PATIENT TRAVEL ASSISTNCE	618	154,500

Part IV

Supplemental Information. Provide the information required in Part I, line 2, Part III, column (b), and any other additional information.

Return Reference

Explanation

SCHEDULE I, PAGE 1, PART I, LINE 2

FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATEINTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.

Schedule I (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" to Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990. SchJMediumBullet

See separate instructions.
SchJMediumBullet

Information about Schedule J (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked in line 1a? ..

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? ................

Yes

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Yes

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 5a or 5b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 6a or 6b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Yes

Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................

If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2013

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(1)JOHN E WALTERPRES&CEO TERM 2/2014	(i) (ii)	606,473		21,886	32,130	31,216	691,705
(2)LOUIS J DEGENNAROPRESIDENT & CEO	(i) (ii)	380,451	42,584	23,165	71,667	22,640	540,507
(3)JAMES T NANGLESVP&CFO TERM 9/2013	(i) (ii)	155,599		252,803	15,606	26,767	450,775
(4)LISA STOCKMONEVP-CHIEF MKTG OFFIC	(i) (ii)	294,428	36,000	18,027	18,749	17,075	384,279
(5)GEORGE J OMIROSEVP-CHIEF CAMP&FIELD	(i) (ii)	299,361	15,000	20,357	25,500	19,753	379,971
(6)MARK VELLECACHIEF POLICY & ADVOC	(i) (ii)	289,161	21,000	13,161	17,351	30,429	371,102
(7)MARK ROITHMAYRCHIEF DEVELOPMENT OF	(i) (ii)	301,719		18,995		25,806	346,520
(8)BRIAN ROSENCHIEF POLICY & ADVOC	(i) (ii)	256,998	13,291	12,208	5,594	28,055	316,146

Schedule J (Form 990) 2013

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II.
Also complete this part for any additional information.

Return Reference	Explanation
SCHEDULE J, PAGE 1, PART I, LINE 4	LOUIS J. DEGENNARO 0 46,667 0 JAMES T. NANGLE 238,870 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7	BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF GROSS REVENUE EXCEEDING BUDGTED GROSS REVENUE, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B) (II).

Schedule J (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Information about Schedule M (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	122	890,755	MARKET VALUE
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...	X	51
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( PRINTED ITEMS )	X	13
26 Other ( FURNITURE&EQUIP )	X	4
27 Other ( VARIOUS )	X	60
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that

it must hold for at least three years from the date of the initial contribution, and which is not required to be used

for exempt purposes for the entire holding period? ..................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization did not report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2013)

Page 2

Part II

Supplemental Information. Provide the information required by Part I, lines 30b,
32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
SCHEDULE M, PAGE 1, PART I, LINE 33	LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.
SCHEDULE M, PAGE 2, PART II	PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS.

Schedule M (Form 990) (2013)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Information about Schedule O (Form 990 or 990-EZ) and its instructions is at
www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Return Reference	Explanation
FORM 990, PAGE 2, PART III, LINE 4A	TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2014, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 78 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2014, FOR THE THIRD YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGEIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORAMTION TO IMPROVE PATIENT OUTCOMES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLI
FORM 990, PAGE 2, PART III, LINE 4B	PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 742,148 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2014. FINANCIAL ASSISTANCE IN 2014, A COMBINED 51,924,134 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,523,615),CO-PAY ASSISTANCE PROGRAMS (49,246,019) AND THE LLS PATIENT TRAVEL ASSISTANCE PROGRAM (154,500). PATIENT FINANCIAL ASSISTANCE PROGRAMS FOR MORE THAN 47 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL ASSISTANCE PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL ASSISTANCE FUNDS ARE SUBJECT TO AVAILABILITY. - 25,854 PATIENTS RECEIVED PATIENT FINANCIAL ASSISTANCE IN 2014. CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,640 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2014 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 27,459 PATIENT AND CAREGIVER PARTICIPANTS ACROSS THE US IN 2014 - 10,798 HEALTHCARE PROFESSIONAL PARTICIPANTS ACROSS THE US IN 2014 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 1,075 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 22 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2014. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 344 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 618 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 13,811 PARTICIPANTS IN FAMILY SUPPORT GROUPS ACROSS THE US IN 2014 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 5,616 FIRST CONNECTIONS ACROSS THE US IN 2014.
FORM 990, PAGE 2, PART III, LINE 4C	NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 48,326 INQUIRIES IN 2014 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH, SPANISH AND FRENCH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2014, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.
FORM 990, PAGE 2, PART III, LINE 4D	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.
FORM 990, PART V, LINE 4B	CANADA
FORM 990, PAGE 6, PART VI, LINE 4	IN 2013, THE LLS BOARD OF DIRECTORS (BOD) AND THE BOARD OF REPRESENTATIVES (BOR) AUTHORIZED CHANGES TO THE CHAPTERS' INVOLVEMENT IN THE LLS GOVERNANCE. PURSUANT TO THE CHANGES, THE LLS BYLAWS WERE AMENDED IN JANUARY 2014 TO REFLECT THAT THE CHAPTERS, ACTING THROUGH THE CHAPTER CHAIR ASSEMBLY WILL REPLACE THE BOR AND WILL RETAIN OVERSIGHT OVER THE LLS ACTIVITIES AND PROGRAMS AT THE CHAPTER LEVEL. ALL OTHER VOTING RIGHTS AFFORDED TO MEMBERS UNDER THE NEW YORK NOT-FOR-PROFIT CORPORATION LAW (NPCL), INCLUDING THE RIGHT TO ELECT THE LLS ELECTED DIRECTORS, WILL NOW BE VESTED IN A SECOND CLASS OF MEMBERS COMPRISED OF THE LLS BOARD OF DIRECTORS. IN ADDITION, THE LLS BYLAWS WERE AMENDED TO REFLECT THE REQUIREMENTS OF THE NEW YORK NON-PROFIT REVITALIZATION ACT OF 2013. THE ACT REQUIRES LLS TO EXERCISE INCREASED OVERSIGHT OF ITS AUDIT AS WELL AS ITS ACCOUNTING AND FINANCIAL REPORTING PROCESSES. THE AMENDMENT INCLUDES ADDITIONAL DUTIES THAT THE AUDIT COMMITTEE MUST CARRY OUT TO COMPLY WITH THE ACT.
FORM 990, PAGE 6, PART VI, LINE 6	THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
FORM 990, PAGE 6, PART VI, LINE 7A	THE LLS BOARD OF DIRECTORS ELECT THE ELECTED DIRECTORS AND HAVE ALL OF THE OTHER VOTING RIGHTS AFFORDED TO MEMBERS UNDER THE NEW YORK NOT-FOR-PROFIT CORPORATION LAW.
FORM 990, PAGE 6, PART VI, LINE 7B	SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
FORM 990, PAGE 6, PART VI, LINE 11B	THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE 990 WAS POSTED TO THE BOARD BOOKS SITE AND WAS FORMALLY APPROVED BY THE AUDIT COMMITTEE ON JANUARY 29, 2015 AND AT THE FULL BOARD MEETING ON JANUARY 30, 2015.
FORM 990, PAGE 6, PART VI, LINE 12C	ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 15A	THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE MOST RECENT SURVEY WAS CONDUCTED IN 2013. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15B	THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES IN 2013 AND COMPARED THIS TO THE OTHER OFFICER'S SALARY AND DETERMINED THAT IT WAS APPROPRIATE. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
FORM 990, PAGE 6, PART VI, LINE 17	ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19	THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE, WHEN CHANGES ARE MADE, AS PART OF THE 990 AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
FORM 990, PART XI, LINE 9	LLS CANADA REVENUE 12,662,047 LSRP CONTRIBUTION -58,002 ROUNDING 1 LLS CANADA EXPENSES -11,853,901 FOREIGN CURRENCY TRANSALATION ADJUSTMENT -153,433 ROUNDING 4 WRITE-OFF OF CONTRIBUTIONS RECEIVABLE -3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR 304,286
FORM 990, PART XI, LINE 9	CHANGE IN NET ASSETS LLS CANADA -724,448 LSRP CONNTRIBUTION 58,002 FINANCIAL STATEMENT ROUNDING -101 FOREIGN CURRENCY TRANSLATION 153,433 UNREALIZED CHANGE ON INVESTMENTS -6,349,371 WRITE-OFF OF CONTRIBUTIONS RECEIVABLES 3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR -304,286 CHANGE IN NET ASSETS PER FORM 990 (PART XI, LINE 3) -7,102,295

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990. MediumBullet

See separate instructions.
MediumBullet

Information about Schedule R (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC
INC

Employer identification number

13-5644916

Part I

Identification of Disregarded Entities Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1) THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO M2J4P8 CA	PART VII	CA			LLS INC	Yes
(2) THE LLS RESEARCH PROGRAMS INC 1311 MAMARONECK AVENUE WHITE PLAINS,NY10605 13-3470494	PART VII	DE	501C3	11B	LLS INC	Yes
(3) THE LLS RESEARCH FOUNDATION 1311 MAMARONECK AVENUE WHITE PLAINS,NY10605 13-3709252	PART VII	DE	501C3	11B	LLS INC	Yes

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2013

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	Yes	No

Schedule R (Form 990) 2013

Page 3

Part V

Transactions With Related Organizations Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest (ii) annuities (iii) royalties or (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .

b Gift, grant, or capital contribution to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

c Gift, grant, or capital contribution from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

d Loans or loan guarantees to or for related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

e Loans or loan guarantees by related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

f Dividends from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

g Sale of assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

h Purchase of assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

i Exchange of assets with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

j Lease of facilities, equipment, or other assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

k Lease of facilities, equipment, or other assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .

l Performance of services or membership or fundraising solicitations for related organization(s) . . . . . . . . . . . . . . . . . . . .

m Performance of services or membership or fundraising solicitations by related organization(s) . . . . . . . . . . . . . . . . . . . .

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) . . . . . . . . . . . . . . . . . . . . .

Yes

o Sharing of paid employees with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

p Reimbursement paid to related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

q Reimbursement paid by related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

r Other transfer of cash or property to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

s Other transfer of cash or property from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) THE LEUKEMIA & LYMPHOMA SOCIETY	D	87,012	COST
(2) OF CANADA
(3) THE LLS RESEARCH PROGRAMS INC	C	58,002	COST

Schedule R (Form 990) 2013

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V?UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V?UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2013

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R (see instructions).

Return Reference	Explanation
SCHEDULE R	THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.

Schedule R (Form 990) 2013

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	28
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	28
5	Total number of individuals employed in calendar year 2013 (Part V, line 2a) ......	5	1,439
6	Total number of volunteers (estimate if necessary) .............	6	3,000,000
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, line 34 .........	7b

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	279,789,665	302,437,152
9	Program service revenue (Part VIII, line 2g) .........		0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	8,133,222	6,995,117
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	2,435,580	663,718
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)...................	290,358,467	310,095,987
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	117,726,007	130,249,475
14	Benefits paid to or for members (Part IX, column (A), line 4).....		0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	90,034,581	94,185,722
16a	Professional fundraising fees (Part IX, column (A), line 11e).....	10,134,488	7,178,370
b	Total fundraising expenses (Part IX, column (D), line 25) 50,314,811
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	89,083,589	85,584,715
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	306,978,665	317,198,282
19	Revenue less expenses. Subtract line 18 from line 12.......	-16,620,198	-7,102,295
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	236,325,556	242,581,527
21	Total liabilities (Part X, line 26).............	135,316,123	145,444,419
22	Net assets or fund balances. Subtract line 21 from line 20.....	101,009,433	97,137,108

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 82,095,311 including grants of $ 78,325,341 ) (Revenue $ )
	A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. (CONTINUED ON SCHEDULE O) TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2014, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 78 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2014, FOR THE THIRD YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGEIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS

4b	(Code: ) (Expenses $ 96,728,148 including grants of $ 51,924,134 ) (Revenue $ )
	B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1,129,813 PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. (CONTINUED ON SCHEDULE O) LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 742,148 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2014. FINANCIAL ASSISTANCE IN 2014, A COMBINED 51,924,134 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,523,615),CO-PAY ASSISTANCE PROGRAMS (49,246,019) AND THE LLS PATIENT TRAVEL ASSISTANCE PROGRAM (154,500). PATIENT FINANCIAL ASSISTANCE PROGRAMS FOR MORE THAN 47 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL ASSISTANCE PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL ASSISTANCE FUNDS ARE SUBJECT TO AVAILABILITY. - 25,854 PATIENTS RECEIVED PATIENT FINANCIAL ASSISTANCE IN 2014. CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,640 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2014 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 27,459 PATIENT AND CAREGIVER PARTICIPANTS ACROSS THE US IN 2014 - 10,798 HEALTHCARE PROFESSIONAL PARTICIPANTS ACROSS THE US IN 2014 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 1,075 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 22 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2014. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 344 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 618 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 13,811 PARTICIPANTS IN FAMILY SUPPORT GROUPS ACROSS THE US IN 2014 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 5,616 FIRST CONNECTIONS ACROSS THE US IN 2014.

4c	(Code: ) (Expenses $ 42,730,205 including grants of $ ) (Revenue $ )
	C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION INFORMATION RESOURCE CENTER PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. (CONTINUED ON SCHEDULE O) LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 48,326 INQUIRIES IN 2014 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH, SPANISH AND FRENCH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2014, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.

	(Code: ) (Expenses $ 19,047,085 including grants of $ ) (Revenue $ )
	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ 19,047,085 including grants of $ ) (Revenue $ )
4e	Total program service expenses240,600,749

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)............	3,229,133	393,657

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512-514
1a	Federated campaigns..1a		2,194,082
b	Membership dues....1b
c	Fundraising events....1c		163,590,328
d	Related organizations...1d		58,002
e	Government grants (contributions)1e

f	All other contributions, gifts, grants, and similar amounts not included above1f		136,594,740

g	Noncash contributions included in lines 1a-1f:$		890,755
h	Total. Add lines 1a-1f.......			302,437,152
			Business Code
2a
b
c
d
e
f	All other program service revenue .
g	Total. Add lines 2a–2f........
3	Investment income (including dividends, interest, and other similar amounts).......			1,200,545			1,200,545
4	Income from investment of tax-exempt bond proceeds..
5	Royalties...........			3,320			3,320
		(i) Real	(ii) Personal
6a	Gross rents
b	Less: rental expenses
c	Rental income or (loss)
d	Net rental income or (loss).......
		(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	90,871,363
b	Less: cost or other basis and sales expenses	85,076,791
c	Gain or (loss)	5,794,572
d	Net gain or (loss)..........			5,794,572			5,794,572
8a	Gross income from fundraising events (not including $ 163,590,328 of contributions reported on line 1c). See Part IV, line 18 ..
	a		27,272,894
b	Less: direct expenses ...b		27,272,894
c	Net income or (loss) from fundraising events..
9a	Gross income from gaming activities. See Part IV, line 19 ...
	a		795,990
b	Less: direct expenses ...b		240,471
c	Net income or (loss) from gaming activities...			555,519			555,519
10a	Gross sales of inventory, less returns and allowances .
	a
b	Less: cost of goods sold ..b
c	Net income or (loss) from sales of inventory..
Miscellaneous Revenue			Business Code
11a	OTHER MISCELLANEOUS		900099	104,879			104,879
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			104,879
12	Total revenue. See Instructions......			310,095,987			7,658,835


				(A) Beginning of year		(B) End of year
1	Cash–non-interest-bearing .............			5,620,937	1	6,268,949
2	Savings and temporary cash investments .........			19,656,020	2	20,220,498
3	Pledges and grants receivable, net ...........			7,252,079	3	8,575,572
4	Accounts receivable, net .............			81,719	4	311
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
					6
7	Notes and loans receivable, net .............				7
8	Inventories for sale or use ..............				8
9	Prepaid expenses and deferred charges ..........			4,851,345	9	4,955,078
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	31,199,936
b	Less: accumulated depreciation .....	10b	14,790,328	10,594,159	10c	16,409,608
11	Investments—publicly traded securities ..........			112,406,398	11	125,935,503
12	Investments—other securities. See Part IV, line 11 .....			75,862,899	12	60,216,008
13	Investments—program-related. See Part IV, line 11 .....				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........				15
16	Total assets. Add lines 1 through 15 (must equal line 34)......			236,325,556	16	242,581,527
17	Accounts payable and accrued expenses .........			20,652,928	17	20,275,231
18	Grants payable .................			80,460,957	18	99,130,986
19	Deferred revenue ................			34,202,238	19	26,038,202
20	Tax-exempt bond liabilities .............				20
21	Escrow or custodial account liability. Complete Part IV of Schedule D..				21
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........				22
23	Secured mortgages and notes payable to unrelated third parties ..				23
24	Unsecured notes and loans payable to unrelated third parties ....				24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................				25
26	Total liabilities. Add lines 17 through 25.........			135,316,123	26	145,444,419
	Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............			90,324,737	27	67,582,758
28	Temporarily restricted net assets ...........			7,775,266	28	26,592,408
29	Permanently restricted net assets ...........			2,909,430	29	2,961,942
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........				30
31	Paid-in or capital surplus, or land, building or equipment fund .....				31
32	Retained earnings, endowment, accumulated income, or other funds				32
33	Total net assets or fund balances ...........			101,009,433	33	97,137,108
34	Total liabilities and net assets/fund balances ........			236,325,556	34	242,581,527

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes,"the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)......................................	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A).......................................	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471)..............................	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621)...............................................	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships. (see Instructions for Form 8865)....................................	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see Instructions for Form 5713)................................................	Yes	No